小規模な研究により、CAR-T細胞療法がHIVの長期的な管理に向けた新しい手法となる可能性が示された。特定のガンの治療にすでに用いられているこの手法は、患者自身の免疫細胞を遺伝子改変するものだ。
研究者らは、2人の被験者において肯定的な初期兆候が見られたことを受け、HIV治療への転用を試みている。この改変細胞は、継続的な介入なしにウイルスを抑制する一助となる可能性がある。
CAR-T細胞療法、HIV抑制に初期の可能性
AIによるレポート
関連記事
AIによって生成された画像
CAR-T therapy achieves complete remission of three autoimmune diseases in German woman
AIによるレポート AIによって生成された画像
A 47-year-old woman bedridden with autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome has achieved complete remission after CAR-T cell therapy at University Hospital Erlangen in Germany. Treated by Fabian Müller after nine failed therapies, she recovered rapidly and remains healthy over a year later without medication—the first simultaneous treatment of multiple autoimmune diseases with this method.
A study published on Monday in Nature Microbiology confirms long-term HIV remission in the «Oslo patient», a 62-year-old man treated for myelodysplasia via stem cell transplant from his brother carrying the CCR5 Delta 32 mutation. He has been off antiretrovirals for four years with no detectable virus. This brings the total to ten patients deemed cured this way.
AIによるレポート
Researchers have found that making cancer cells stiffer can enhance the effectiveness of car t-cell therapy against aggressive tumors. In experiments with mice, the approach led to complete tumor disappearance in some cases. The findings were presented recently at a conference in London.
An experimental therapy using stem cells from young donors has shown promise in improving mobility for frail older people. In a trial involving 148 participants, infusions of laromestrocel led to significant gains in walking distance. Researchers highlight its potential to address biological roots of frailty.
AIによるレポート
A health ministry expert panel has conditionally approved two regenerative medicine products derived from induced pluripotent stem (iPS) cells for treating Parkinson's disease and severe heart disease. This marks a potential world first in commercializing Nobel Prize-winning stem cell technology. The approval, based on small-scale clinical trials confirming safety and presumed efficacy, requires post-market verification within seven years.
2026/05/16 00:33